428 related articles for article (PubMed ID: 32757492)
1. Large granular lymphocytosis induced by dasatinib.
Fernandes F; Ramalho R; Barreira R; Silveira M; Bain BJ
Am J Hematol; 2021 Mar; 96(3):395-396. PubMed ID: 32757492
[No Abstract] [Full Text] [Related]
2. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
McGrath K; Stein B; Kalhagen L; Leighton L
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
[No Abstract] [Full Text] [Related]
4. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
Nagata Y; Ohashi K; Fukuda S; Kamata N; Akiyama H; Sakamaki H
Int J Hematol; 2010 Jun; 91(5):799-807. PubMed ID: 20405252
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
Watanabe N; Takaku T; Takeda K; Shirane S; Toyota T; Koike M; Noguchi M; Hirano T; Fujiwara H; Komatsu N
Int J Hematol; 2018 Dec; 108(6):588-597. PubMed ID: 30151740
[TBL] [Abstract][Full Text] [Related]
6. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
Kim DH; Kamel-Reid S; Chang H; Sutherland R; Jung CW; Kim HJ; Lee JJ; Lipton JH
Haematologica; 2009 Jan; 94(1):135-9. PubMed ID: 19066329
[TBL] [Abstract][Full Text] [Related]
7. Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia.
Adattini JA; Gross AS; Doo NW; McLachlan AJ
Haematologica; 2023 Aug; 108(8):2224-2228. PubMed ID: 36655426
[No Abstract] [Full Text] [Related]
8. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.
Yim E; Choi YG; Nam YJ; Lee J; Kim JA
Korean J Intern Med; 2018 Mar; 33(2):446-448. PubMed ID: 26961484
[No Abstract] [Full Text] [Related]
10. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Valent JN; Schiffer CA
Leuk Res; 2011 Jan; 35(1):e1-3. PubMed ID: 20888043
[No Abstract] [Full Text] [Related]
11. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
[TBL] [Abstract][Full Text] [Related]
12. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Hagihara M; Iriyama N; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Oncol Rep; 2016 Nov; 36(5):2976-2982. PubMed ID: 27665844
[TBL] [Abstract][Full Text] [Related]
13. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
[No Abstract] [Full Text] [Related]
14. Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature.
Hickman K; Diaz E; Graham R; Adams R; Ngwube A
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e665-e667. PubMed ID: 31688632
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib-induced loss of eyebrows.
Naithani R
Br J Haematol; 2017 Nov; 179(3):362. PubMed ID: 28737227
[No Abstract] [Full Text] [Related]
17. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas S
Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
[TBL] [Abstract][Full Text] [Related]
18. Should vascular effects of newer treatments be addressed more completely?
Yang EH; Watson KE; Herrmann J
Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
[No Abstract] [Full Text] [Related]
19. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
20. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]